Viva Biotech Holdings(HK:1873)
HK$1.30-0.00 (-0.38%)
HK:1873
Viva Biotech Holdings financials statements
HK$1.30
At close:-0.00 (-0.38%)
Want to see HK:1873 full AI Analyst Report?
Viva Biotech Holdings (1873) Ratios
4 Followers
Viva Biotech Holdings Ratios
HK:1873's free cash flow for Q2 2026 was ¥239.63M. For the 2026 fiscal year, HK:1873's free cash flow was decreased by ¥-95.52M and operating cash flow was ¥335.15M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.50 | 1.67 | 1.32 | 0.73 | 2.14 |
| Quick Ratio | 1.26 | 1.42 | 1.15 | 0.60 | 1.89 |
| Cash Ratio | 0.79 | 0.84 | 0.68 | 0.25 | 0.86 |
| Solvency Ratio | 0.13 | 0.11 | 0.02 | -0.08 | 0.10 |
| Operating Cash Flow Ratio | 0.15 | 0.33 | 0.25 | 0.14 | 0.08 |
| Short-Term Operating Cash Flow Coverage | 0.21 | 0.68 | 0.40 | 0.20 | 0.33 |
| Net Current Asset Value | ¥ -1.08B | ¥ -1.36B | ¥ -1.73B | ¥ -2.38B | ¥ -2.15B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.18 | 0.18 | 0.26 | 0.36 | 0.33 |
| Debt-to-Equity Ratio | 0.33 | 0.34 | 0.52 | 0.78 | 0.68 |
| Debt-to-Capital Ratio | 0.25 | 0.25 | 0.34 | 0.44 | 0.40 |
| Long-Term Debt-to-Capital Ratio | 0.08 | 0.16 | 0.20 | 0.20 | 0.38 |
| Financial Leverage Ratio | 1.80 | 1.85 | 2.02 | 2.20 | 2.06 |
| Debt Service Coverage Ratio | 0.35 | 0.59 | 0.31 | 0.19 | 0.78 |
| Interest Coverage Ratio | 5.29 | 4.26 | 1.09 | 1.46 | 1.29 |
| Debt to Market Cap | 0.34 | 0.73 | 1.05 | 0.96 | 0.36 |
| Interest Debt Per Share | 0.58 | 0.63 | 1.07 | 1.59 | 1.48 |
| Net Debt to EBITDA | 0.55 | 0.80 | 2.22 | 4.91 | 5.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 37.91% | 34.60% | 34.26% | 34.28% | 30.94% |
| EBIT Margin | 11.17% | 11.56% | 8.94% | 11.18% | 11.26% |
| EBITDA Margin | 23.38% | 21.54% | 18.14% | 18.34% | 17.58% |
| Operating Profit Margin | 11.17% | 11.56% | 8.94% | 11.32% | 11.26% |
| Pretax Profit Margin | 18.39% | 14.88% | -2.60% | -19.30% | 16.53% |
| Net Profit Margin | 12.71% | 8.42% | -5.39% | -22.21% | 13.67% |
| Continuous Operations Profit Margin | 15.57% | 11.17% | -4.63% | -21.19% | 14.28% |
| Net Income Per EBT | 69.11% | 56.57% | 207.52% | 115.09% | 82.70% |
| EBT Per EBIT | 164.55% | 128.75% | -29.04% | -170.47% | 146.77% |
| Return on Assets (ROA) | 3.05% | 2.37% | -1.56% | -6.67% | 3.57% |
| Return on Equity (ROE) | 5.50% | 4.40% | -3.15% | -14.66% | 7.35% |
| Return on Capital Employed (ROCE) | 3.34% | 3.88% | 3.26% | 5.13% | 3.33% |
| Return on Invested Capital (ROIC) | 2.42% | 2.66% | 2.81% | 3.96% | 2.94% |
| Return on Tangible Assets | 4.64% | 3.69% | -2.38% | -9.99% | 5.37% |
| Earnings Yield | 5.81% | 9.69% | -6.54% | -18.12% | 3.92% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.75 | 4.55 | 5.29 | 5.34 | 4.90 |
| Payables Turnover | 5.06 | 4.20 | 5.77 | 4.80 | 5.17 |
| Inventory Turnover | 3.20 | 4.76 | 5.46 | 4.80 | 6.27 |
| Fixed Asset Turnover | 1.10 | 1.24 | 1.30 | 1.23 | 1.22 |
| Asset Turnover | 0.24 | 0.28 | 0.29 | 0.30 | 0.26 |
| Working Capital Turnover Ratio | 2.38 | 3.19 | -18.19 | 14.71 | 1.15 |
| Cash Conversion Cycle | 174.96 | 69.99 | 72.58 | 68.38 | 62.15 |
| Days of Sales Outstanding | 132.96 | 80.29 | 68.99 | 68.41 | 74.54 |
| Days of Inventory Outstanding | 114.16 | 76.61 | 66.89 | 76.09 | 58.21 |
| Days of Payables Outstanding | 72.17 | 86.91 | 63.30 | 76.11 | 70.60 |
| Operating Cycle | 247.13 | 156.90 | 135.88 | 144.50 | 132.75 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.09 | 0.18 | 0.20 | 0.20 | 0.04 |
| Free Cash Flow Per Share | 0.04 | 0.09 | 0.10 | 0.07 | -0.25 |
| Dividend Paid and CapEx Coverage Ratio | 1.75 | 1.95 | 2.04 | 1.55 | 0.13 |
| Capital Expenditure Coverage Ratio | 1.75 | 1.95 | 2.04 | 1.55 | 0.14 |
| Operating Cash Flow Coverage Ratio | 0.15 | 0.29 | 0.20 | 0.14 | 0.03 |
| Operating Cash Flow to Sales Ratio | 0.12 | 0.19 | 0.18 | 0.16 | 0.04 |
| Free Cash Flow Yield | 2.33% | 10.56% | 11.01% | 4.69% | -6.65% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 17.96 | 10.32 | -15.29 | -5.52 | 25.50 |
| Price-to-Sales (P/S) Ratio | 2.19 | 0.87 | 0.82 | 1.23 | 3.48 |
| Price-to-Book (P/B) Ratio | 0.95 | 0.45 | 0.48 | 0.81 | 1.87 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 42.97 | 9.47 | 9.08 | 21.33 | -15.05 |
| Price-to-Operating Cash Flow Ratio | 18.36 | 4.61 | 4.63 | 7.55 | 94.21 |
| Price-to-Earnings Growth (PEG) Ratio | 1.20 | -0.04 | 0.19 | 0.02 | -0.16 |
| Enterprise Value Multiple | 9.90 | 4.83 | 6.76 | 11.60 | 24.83 |
| Enterprise Value | 4.00B | 2.07B | 2.64B | 5.06B | 9.19B |
| EV to EBITDA | 9.90 | 4.83 | 6.76 | 11.60 | 24.83 |
| EV to Sales | 2.32 | 1.04 | 1.23 | 2.13 | 4.37 |
| EV to Free Cash Flow | 45.49 | 11.34 | 13.51 | 37.02 | -18.85 |
| EV to Operating Cash Flow | 19.43 | 5.53 | 6.89 | 13.11 | 118.03 |
| Tangible Book Value Per Share | 0.66 | 0.61 | 0.57 | 0.52 | 0.64 |
| Shareholders’ Equity Per Share | 1.71 | 1.78 | 1.90 | 1.91 | 2.05 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | 0.25 | -0.78 | -0.10 | 0.14 |
| Revenue Per Share | 0.74 | 0.93 | 1.11 | 1.26 | 1.10 |
| Net Income Per Share | 0.09 | 0.08 | -0.06 | -0.28 | 0.15 |
| Tax Burden | 0.69 | 0.57 | 2.08 | 1.15 | 0.83 |
| Interest Burden | 1.65 | 1.29 | -0.29 | -1.73 | 1.47 |
| Research & Development to Revenue | 0.06 | 0.04 | 0.06 | 0.06 | 0.04 |
| SG&A to Revenue | 0.21 | 0.18 | 0.13 | 0.11 | 0.11 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Income Quality | 0.96 | 1.26 | -6.85 | -0.73 | 0.27 |
Currency in CNY
